Viatris VTRS
NASDAQ VTRS
$16.51 -0.10 (-0.60%)
As of: Sep 9, 2026 · 2:29 PM EDT

Viatris (VTRS) Non Operating Interest Expenses (2020 - 2026)

Viatris (VTRS) posted Non Operating Interest Expenses of $120.7 million for Q2 2026, little changed on a QoQ basis from $120.1 million in Q1 2026, and up 3.52% year-over-year from $116.6 million in Q2 2025.

Analysis

Viatris (VTRS) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends

Viatris has reported Non Operating Interest Expenses for 7 years, with the latest figure at $120.7 million in Q2 2026.

  • On a quarterly basis, Non Operating Interest Expenses rose 3.52% year-over-year to $120.7 million in Q2 2026; TTM through Jun 2026 was $480.0 million, a 3.6% decrease from a year earlier, with the FY2025 full-year figure at $471.3 million, down 14.31% from the prior year.
  • Non Operating Interest Expenses was $120.7 million for Q2 2026 at Viatris, roughly flat from $120.1 million in the prior quarter.
  • The five-year high for Non Operating Interest Expenses was $153.2 million in Q3 2022, with the low at $115.5 million in Q1 2025.
  • Average Non Operating Interest Expenses over 5 years is $134.9 million, with a median of $141.2 million recorded in 2023.
  • The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses dropped 20.03% in 2025, then rose 3.98% in 2026.
  • Over 5 years, Non Operating Interest Expenses stood at $147.1 million in 2022, then decreased by 4.21% to $140.9 million in 2023, then declined by 14.69% to $120.2 million in 2024, then decreased by 0.5% to $119.6 million in 2025, then grew by 0.92% to $120.7 million in 2026.
  • The last three Non Operating Interest Expenses figures came in at $120.7 million (Q2 2026), $120.1 million (Q1 2026), and $119.6 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Teva Pharmaceutical Industries 42.57 Bn 38.91 Bn 2.15 Bn -
2 Viatris 19.20 Bn 18.31 Bn 1.46 Bn 120.70 Mn
3 Dr Reddys Laboratories 9.86 Bn 9.69 Bn 396.53 Mn -13.26 Mn
4 Amneal Pharmaceuticals 5.48 Bn 5.35 Bn 334.51 Mn -
5 Bausch Health Companies 2.36 Bn 520.75 Mn 2.10 Bn 396.00 Mn
6 Alvotech 1.50 Bn 1.36 Bn 2.56 Mn -41.02 Mn
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn -
8 Amphastar Pharmaceuticals 995.52 Mn 705.40 Mn 93.47 Mn 6.66 Mn
9 Fennec Pharmaceuticals 406.25 Mn 365.00 Mn 17.15 Mn 3,000.00
10 RedHill Biopharma 176.59 Mn 176.59 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 120.70 Mn
Mar 31, 2026 120.10 Mn
Dec 31, 2025 119.60 Mn
Sep 30, 2025 119.60 Mn
Jun 30, 2025 116.60 Mn
Mar 31, 2025 115.50 Mn
Dec 31, 2024 120.20 Mn
Sep 30, 2024 145.60 Mn
Jun 30, 2024 145.80 Mn
Mar 31, 2024 138.40 Mn
Dec 31, 2023 140.90 Mn
Sep 30, 2023 141.50 Mn
Jun 30, 2023 143.70 Mn
Mar 31, 2023 147.00 Mn
Dec 31, 2022 147.10 Mn
Sep 30, 2022 153.20 Mn
Jun 30, 2022 145.90 Mn
Mar 31, 2022 146.20 Mn
Dec 31, 2021 148.20 Mn
Sep 30, 2021 151.90 Mn